CTLA4 and non-small cell lung carcinoma: In the phase III CheckMate 227 trial, treatment-naive patients with advanced NSCLC without molecular drivers were randomized to receive a combination of nivolumab plus ipilimumab (anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)), standard chemotherapy, or nivolumab as monotherapy.